Clinical Trial News and Research RSS Feed - Clinical Trial News and Research

Mymetics' innovative HIV vaccine candidate to enter new preclinical trial

Mymetics' innovative HIV vaccine candidate to enter new preclinical trial

Mymetics Corporation, a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate will enter a new preclinical trial to confirm excellent results obtained in a previous trial. [More]
Brain cancer patients can benefit from Rapamycin drug

Brain cancer patients can benefit from Rapamycin drug

Every day, organ transplant patients around the world take a drug called rapamycin to keep their immune systems from rejecting their new kidneys and hearts. [More]
CytRx begins aldoxorubicin Phase 2b clinical trial in patients with extensive-stage SCLC

CytRx begins aldoxorubicin Phase 2b clinical trial in patients with extensive-stage SCLC

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of a global Phase 2b clinical trial evaluating aldoxorubicin compared to topotecan in subjects with extensive-stage small cell lung cancer (SCLC) who have relapsed or were refractory to prior chemotherapy. [More]
Brain & Behavior Research Foundation to honor 8 scientists for achievements in psychiatric research

Brain & Behavior Research Foundation to honor 8 scientists for achievements in psychiatric research

The Brain & Behavior Research Foundation will honor eight scientists with its 2014 Outstanding Achievement Prizes for work delving into psychiatric disorders that affect one in four people. The awards, which celebrate the transformative power of neuroscience and psychiatric research to improve the lives of people with mental illness, will be presented at the Foundation's National Awards Dinner at the Pierre Hotel. [More]
Trastuzumab offers better outcome than lapatinib for HER2-positive breast cancer patients

Trastuzumab offers better outcome than lapatinib for HER2-positive breast cancer patients

Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a Mayo Clinic researcher. [More]
Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC). [More]
Galmed Pharmaceuticals purchases EndoPAT devices, accessories from Itamar Medical

Galmed Pharmaceuticals purchases EndoPAT devices, accessories from Itamar Medical

Galmed Pharmaceuticals Ltd. ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today that it purchased 60 EndoPATâ„¢ devices and accessories from Itamar Medical Ltd. [More]

Manzo Pharmaceuticals reports successful testing of lactase producing probiotic, Lacto-Freedom

Manzo Pharmaceuticals, Inc., today announced at the three month mark in a six month animal study, that the results of the lactase producing probiotic, Lacto-Freedomâ„¢, has been very successful. [More]
Curemark Founder to get Northstar Award for breakthrough autism research

Curemark Founder to get Northstar Award for breakthrough autism research

Curemark, a leading drug research and development company focused on the treatment of neurological and other diseases, is proud to announce that Dr. Joan Fallon, Founder and CEO, will receive Springboard Enterprises' Northstar Award, as recognition for her entrepreneurial leadership and achievements in autism research. [More]
FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung cancer and ovarian cancer. [More]
Lung-MAP, ALCHEMIST clinical trials offer innovative study designs for lung cancer patients

Lung-MAP, ALCHEMIST clinical trials offer innovative study designs for lung cancer patients

The recent launch of two clinical trials offer innovative study designs for patients with lung cancer. These clinical trials are the direct result of a National Cancer Institute sponsored workshop chaired by Drs. Fred R. Hirsch, Shakun Malik and Claudio Dansky- Ullman, that brought together the NCI Thoracic Malignancies Steering Committee, the US Food and Drug Administration, academicians, clinicians as well as industry and government stakeholders to discuss issues and challenges related to clinical trial design and biomarkers for lung cancer targeted-therapies. [More]
CVRx Barostim neo System receives CE Mark approval from NSAI for treatment of heart failure

CVRx Barostim neo System receives CE Mark approval from NSAI for treatment of heart failure

CVRx, Inc., a private medical device company, announced today it received CE Mark approval from the National Standards Authority of Ireland of the Barostim neo System for the treatment of heart failure. [More]
NIH-funded clinical trial aims to restore vision in people who have lost vision due to IIH

NIH-funded clinical trial aims to restore vision in people who have lost vision due to IIH

In an NIH-funded clinical trial, led at Saint Louis University by professor of ophthalmology Sophia Chung, M.D., researchers aim to bring sight back to those who have lost vision due to idiopathic intracranial hypertension. [More]
Lung cancer clinical trials exclude substantial proportion of patients due to prior cancer

Lung cancer clinical trials exclude substantial proportion of patients due to prior cancer

Lung cancer clinical trials exclude a substantial proportion of patients due to a history of prior cancer, as shown in an analysis by cancer researchers at UT Southwestern Medical Center. [More]
Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis. [More]
Heart Hospital of Austin becomes first facility in Texas to implant CardioMEMS HF System

Heart Hospital of Austin becomes first facility in Texas to implant CardioMEMS HF System

On Sept. 24, 2014 Heart Hospital of Austin became the first facility in Texas to implant a new miniaturized, wireless monitoring sensor to manage heart failure (HF). The CardioMEMS HF System is the first and only FDA-approved heart failure monitoring device that has been proven to significantly reduce hospital admissions when used by physicians to manage heart failure. [More]
Australian researchers use hookworms to reduce symptoms of celiac disease

Australian researchers use hookworms to reduce symptoms of celiac disease

Australian researchers have achieved groundbreaking results in a clinical trial using hookworms to reduce the symptoms of celiac disease. [More]
MicroBiome Therapeutics' NM 505 drug can improve tolerability of metformin

MicroBiome Therapeutics' NM 505 drug can improve tolerability of metformin

MicroBiome TherapeuticsTM LLC, today reported positive topline results from a proof of concept study testing whether its investigational drug, NM 505, can improve the tolerability of metformin, the first-line therapy for Type 2 diabetes worldwide. [More]
AcelRx plans for resubmission of Zalviso NDA

AcelRx plans for resubmission of Zalviso NDA

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided an update on the plans for the resubmission of the Company's New Drug Application (NDA) for Zalviso (sufentanil sublingual tablet system). [More]
Sumitomo Dainippon Pharma, SanBio to jointly develop SB623 in the U.S. and Canada

Sumitomo Dainippon Pharma, SanBio to jointly develop SB623 in the U.S. and Canada

Sumitomo Dainippon Pharma Co., Ltd. and SanBio Co., Ltd., acting through its U.S. subsidiary SanBio, Inc., announced on September 26 that the two companies have entered into a joint development and license agreement for exclusive marketing rights in the U.S. and Canada ("Agreement") for SB623, a cell therapy for the treatment of patients with chronic stroke discovered and currently under development by SanBio. [More]